Should I buy or sell Zynerba Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZYNE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYNE, but not buy additional shares or sell existing shares. View ZYNE analyst ratings or view top-rated stocks .

What is Zynerba Pharmaceuticals' stock price target for 2024?

3 brokerages have issued twelve-month target prices for Zynerba Pharmaceuticals' shares. Their ZYNE share price targets range from $1.11 to $1.11. On average, they anticipate the company's share price to reach $1.11 in the next year. This suggests that the stock has a possible downside of 14.6%. View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts .

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced its quarterly earnings results on Monday, May, 15th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02.

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA) , GW Pharmaceuticals (GWPH) , Cronos Group (CRON) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Alibaba Group (BABA) , Shopify (SHOP) and Micron Technology (MU) .

When did Zynerba Pharmaceuticals IPO?

Zynerba Pharmaceuticals (ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

NASDAQ:ZYNE

Zynerba Pharmaceuticals (ZYNE) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ZYNE Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.26
▼
$1.34
50-Day Range: $1.21
▼
$1.39
52-Week Range: $0.25
▼
$1.40

Volume: 862,700 shs
Average Volume: 515,333 shs
Market Capitalization: $70.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.11

Stock Analysis

Get Zynerba Pharmaceuticals alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

ZYNE Stock News Headlines

October 31, 2023 | finance.yahoo.com

Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results

October 13, 2023 | fool.com

Why Shares of Harmony Bioscience Are Falling on Friday

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

October 11, 2023 | markets.businessinsider.com

New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies

October 11, 2023 | finance.yahoo.com

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

October 4, 2023 | finance.yahoo.com

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

September 29, 2023 | finance.yahoo.com

20 Countries With Highest Rate of Epilepsy

September 29, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

September 27, 2023 | bizjournals.com

Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal

September 14, 2023 | finance.yahoo.com

Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc

September 14, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

August 16, 2023 | msn.com

HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)

August 15, 2023 | finance.yahoo.com

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

August 14, 2023 | marketwatch.com

Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNE

August 14, 2023 | markets.businessinsider.com

Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher

August 14, 2023 | technews.tmcnet.com

ZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to Shareholders

August 14, 2023 | finance.yahoo.com

HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

July 25, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting

June 29, 2023 | finance.yahoo.com

Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?

June 28, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting

June 20, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

June 13, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting

May 17, 2023 | bizjournals.com

Main Line CBD drug developer plans reverse stock split to boost share price

May 15, 2023 | finanznachrichten.de

Zynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights

May 15, 2023 | investing.com

Zynerba Pharma (ZYNE) Earnings Dates & Reports

May 15, 2023 | msn.com

Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details

See More Headlines

Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2023
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ZYNE
CUSIP: N/A
CIK: 1621443
Web: www.zynerba.com
Phone: (484) 581-7505
Fax: N/A
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.11
High Stock Price Target: $1.11
Low Stock Price Target: $1.11
Potential Upside/Downside: -14.6%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,040,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -90.03%
Return on Assets: -72.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.43
Quick Ratio: 3.43

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.01 per share
Price / Book: 1.29

Miscellaneous

Outstanding Shares: 53,939,000
Free Float: 46,905,000
Market Cap: $70.12 million
Optionable: Optionable
Beta: 1.32

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Armando Anido MBA (Age 65)
Chairman & CEO
Comp: $934.53k
Ms. Terri B. Sebree (Age 65)
Pres
Comp: $729.15k
Mr. James E. Fickenscher (Age 59)
CFO & VP of Corp. Devel. (Leave of Absence)
Comp: $607.62k
Mr. Kenneth T. Jones (Age 59)
VP, Corp. Controller & Interim CFO
Mr. Albert P. Parker II (Age 57)
Chief Legal Officer & Corp. Sec.
Mr. Joseph Apostolico
VP of HR

Key Competitors

View All Competitors

Insiders

ZYNE Stock Analysis - Frequently Asked Questions

Should I buy or sell Zynerba Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZYNE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYNE, but not buy additional shares or sell existing shares.
View ZYNE analyst ratings or view top-rated stocks.
What is Zynerba Pharmaceuticals' stock price target for 2024?: 3 brokerages have issued twelve-month target prices for Zynerba Pharmaceuticals' shares. Their ZYNE share price targets range from $1.11 to $1.11. On average, they anticipate the company's share price to reach $1.11 in the next year. This suggests that the stock has a possible downside of 14.6%.
View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts.
How were Zynerba Pharmaceuticals' earnings last quarter?: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced its quarterly earnings results on Monday, May, 15th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02.

What other stocks do shareholders of Zynerba Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).
When did Zynerba Pharmaceuticals IPO?: Zynerba Pharmaceuticals (ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

This page (NASDAQ:ZYNE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zynerba Pharmaceuticals (ZYNE) Stock Price, News & Analysis

About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)

ZYNE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

ZYNE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info